

PHARMACIA CORP /DE/  
Form 8-K  
April 30, 2002

SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549

-----  
FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): April 16, 2002

PHARMACIA CORPORATION  
(Exact Name of Registrant as Specified in its Charter)

|   |                                       |  |
|---|---------------------------------------|--|
| Delaware<br>(State or Other Jurisdiction<br>of Incorporation)                       | 1-2516<br>(Commission<br>File Number) | 43-0420020<br>(IRS Employer<br>Identification No.) |
| 100 Route 206 North, Peapack, New Jersey<br>(Address of Principal Executive Office) |                                       | 07977<br>(Zip Code)                                |

908-901-8000

-----  
(Registrant's telephone number, including area code)

N/A

-----  
(Former Name or Former Address, if Changed Since Last Report)

Item 2.

Pursuant to existing agreements, the company had rights from Sanofi-Synthelabo, Inc. (Sanofi) to manufacture, sell and market two products in North America: AMBIEN and KERLONE. AMBIEN is a prescription medicine used in the treatment of sleep disorders including insomnia. KERLONE, also a prescription medicine, is used in the treatment of hypertension and cardiovascular disease. Sales of AMBIEN and KERLONE, included in the company's results, were \$902 million and \$5 million for the year ended December 31, 2001, respectively.

From inception of the agreements until December 31, 2001, Pharmacia recorded the sales and expenses of the products and similarly recorded any related assets and

Edgar Filing: PHARMACIA CORP /DE/ - Form 8-K

liabilities. At December 31, 2001, the company relinquished control over the products to Sanofi and accordingly Pharmacia deconsolidated the related operating assets and liabilities. Additionally, the company ceased recording sales and expenses of AMBIEN and KERLONE as of January 1, 2002.

On April 16, 2002, Sanofi exercised its right to acquire all rights to the products in North America in accordance with the agreements. In connection with such acquisition, the company received a payment of \$671 million for its interest. The cash is reflected on the following pro forma consolidated balance sheet, but the portion representing the gain on sale is not included in the pro forma consolidated statement of earnings due to its nonrecurring nature. In the second quarter of 2002, the company plans to record the gain resulting from this payment under the caption of "All other, net" on the company's consolidated statement of earnings.

The following pro forma consolidated balance sheet and pro forma consolidated statement of earnings and the related explanatory notes reflect the impact of this transaction on the company's reported results as of and for the year ended December 31, 2001. The pro forma consolidated balance sheet reflects the transaction as if it were consummated at December 31, 2001. Accordingly, the adjustments to those balances give effect to all events that are directly attributable to the transaction regardless of whether they have a continuing impact or are nonrecurring. The pro forma consolidated statement of earnings reflects the transaction as if it were consummated at January 1, 2001, the beginning of the company's last fiscal year. All amounts of income and expense that are expected to have a continuing impact on the company are reflected as adjustments. Amounts that are not expected to have a continuing impact on the company's results will not be adjusted. The notes that follow the pro forma consolidated balance sheet and pro forma consolidated statement of earnings provide further explanation of the adjustment amounts as appropriate.

The unaudited pro forma consolidated balance sheet and unaudited pro forma consolidated statement of earnings and the related explanatory notes should be read in conjunction with the historical consolidated financial statements and notes thereto and other information included in Pharmacia's 2001 Annual Report to Shareholders, which is incorporated by reference into Pharmacia's Annual Report on Form 10-K for 2001. The unaudited pro forma information presented below is for illustrative purposes only and is not necessarily indicative of the results of operations or financial position that would have actually occurred if the transaction had been consummated on the dates indicated or that may be obtained in the future.

PHARMACIA CORPORATION  
 UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEET  
 AS OF DECEMBER 31, 2001  
 (DOLLARS IN MILLIONS)

|                           | Pharmacia<br>Actual |   | Pro Forma<br>Adjustments | Pro  |
|---------------------------|---------------------|---|--------------------------|------|
| Cash and cash equivalents | \$ 1,276            | A | \$ 536                   | \$ 1 |

Edgar Filing: PHARMACIA CORP /DE/ - Form 8-K

|  |          |         |      |
|--|----------|---------|------|
| Short-term investments                                   | 119      | --      |      |
| Short-term notes receivable-Monsanto                     | 254      | --      |      |
| Trade accounts receivables, net                          | 2,434    | --      | 2    |
| Inventories  | 1,684    | --      | 1    |
| Deferred income taxes                                    | 932      | --      |      |
| Receivables-Monsanto                                     | 87       | --      |      |
| Other  | 880      | --      |      |
| <hr/>  |          |         |      |
| Total Current Assets                                     | 7,666    | 536     | 8    |
| Long-term investments                                    | 288      | --      |      |
| Properties, net  | 4,875    | --      | 4    |
| Goodwill, net of accumulated amortization                | 1,059    | --      | 1    |
| Other intangible assets, net of accumulated amortization | 444      | --      |      |
| Other noncurrent assets                                  | 1,729    | --      | 1    |
| Net assets of discontinued operations                    | 6,316    | --      | 6    |
| <hr/>  |          |         |      |
| Total Assets   | \$22,377 | \$ 536  | \$22 |
| Short-term debt  | \$ 484   | \$ --   | \$   |
| Short-term notes payable-Monsanto                        | 30       | --      |      |
| Accounts payable   | 1,048    | --      | 1    |
| Payables-Monsanto  | 44       | --      |      |
| Compensation and compensated absences                    | 501      | --      |      |
| Dividends payable  | 180      | --      |      |
| Income taxes payable                                     | 685      | B 238   |      |
| Other accrued liabilities                                | 2,031    | C (128) | 1    |
| <hr/>  |          |         |      |
| Total Current Liabilities                                | 5,003    | 110     | 5    |
| Long-term debt   | 2,612    | --      | 2    |
| Guarantee of ESOP debt                                   | 119      | --      |      |
| Postretirement benefit obligation                        | 996      | --      |      |
| Deferred income taxes                                    | 143      | --      |      |
| Other noncurrent liabilities                             | 1,114    | --      | 1    |
| <hr/>  |          |         |      |
| Total Liabilities  | 9,987    | 110     | 10   |
| <hr/>  |          |         |      |
| Preferred stock  | 258      | --      |      |
| Common stock   | 2,970    | --      | 2    |
| Capital in excess of par value                           | 3,499    | --      | 3    |
| Retained earnings  | 11,586   | D 426   | 12   |
| ESOP-related accounts                                    | (294)    | --      |      |
| Treasury stock   | (2,789)  | --      | (2)  |
| Accumulated other comprehensive loss:                    |          |         |      |
| Cumulative translation adjustments                       | (2,892)  | --      | (2)  |
| Unrealized investment gains, net                         | 142      | --      |      |
| Minimum pension liability adjustment                     | (96)     | --      |      |
| Unrealized hedging instrument gains                      | 6        | --      |      |
| <hr/>  |          |         |      |
| Total Shareholders' Equity                               | 12,390   | 426     | 12   |
| <hr/>  |          |         |      |
| Total Liabilities And Shareholders' Equity               | \$22,377 | \$ 536  | \$22 |
| <hr/>  |          |         |      |

## Edgar Filing: PHARMACIA CORP /DE/ - Form 8-K

### NOTES TO UNAUDITED PRO FORMA CONSOLIDATED BALANCE SHEETS

- A - To adjust for the receipt of \$671 for Pharmacia's interest on April 16, 2002 and the payment of \$135 for the settlement of balances payable to Sanofi.
- B - To reflect estimated taxes due on the gain for the sale of Pharmacia's interest at December 31, 2001.
- C - To adjust for the amounts payable to Sanofi net of the equity in the product rights.
- D - To adjust for the retained earnings effect of the aforementioned balance sheet items as follows:
- |   |  |        |
|---|--|--------|
| Pre-tax gain                                      |  | \$ 664 |
| Estimated income tax payable at December 31, 2001 |  | (238)  |
|   |  | -----  |
| Total   |  | \$ 426 |
|   |  | =====  |

PHARMACIA CORPORATION  
 UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF EARNINGS  
 FOR THE YEAR ENDED DECEMBER 31, 2001  
 (DOLLARS IN MILLIONS, EXCEPT PER-SHARE DATA)

|   | Pharmacia<br>Actual |   | Pro Forma<br>Adjustments |    |
|---|---------------------|---|--------------------------|----|
| Net Sales   | \$13,837            | A | \$(907)                  | \$ |
| Cost of products sold                                 | 2,949               | B | (218)                    |    |
| Research and development                              | 2,263               |   | --                       |    |
| Selling, general and administrative                   | 6,034               | C | (36)                     |    |
| Amortization of goodwill                              | 103                 |   | --                       |    |
| Merger and restructuring                              | 673                 |   | --                       |    |
| Interest expense                                      | 255                 |   | --                       |    |
| Interest income                                       | (110)               |   | --                       |    |
| All other, net  | 83                  | D | (220)                    |    |
| Provision for income taxes                            | 296                 | E | (164)                    | F  |
| Earnings from continuing operations                   | \$ 1,291            |   | \$ (269)                 | \$ |
| Earnings from continuing operations per common share: |                     |   |                          |    |
| Basic earnings from continuing operations             | \$ 0.98             | G |                          | \$ |
| Diluted earnings from continuing operations           | 0.97                | G |                          |    |
| Total shares (in millions):                           |                     |   |                          |    |
| Basic   | 1,298               |   |                          |    |
| Diluted   | 1,322               |   |                          |    |

NOTES TO UNAUDITED PRO FORMA CONSOLIDATED STATEMENT OF EARNINGS

## Edgar Filing: PHARMACIA CORP /DE/ - Form 8-K

- A - To adjust for net sales of AMBIEN of \$902 and KERLONE of \$5 for the year ended December 31, 2001.
- B - To adjust for cost of products sold of AMBIEN of \$217 and \$1 of KERLONE for the year ended December 31, 2001.
- C - To adjust for promotional expenses of \$29 and distribution costs of \$7 for the year ended December 31, 2001.
- D - To adjust for net payments made to Sanofi for the year ended December 31, 2001.
- E - Taxes have been estimated at 38 percent based on U.S. federal and state statutory rates for earnings from continuing operations associated with AMBIEN and KERLONE.
- F - As a result of adjusting the tax provision as described in Note E, the pro forma consolidated statement of earnings reflects an effective tax rate of approximately 11 percent. However, the company believes that

this rate is not indicative of current operations and expects an effective rate of approximately 25 percent to be realized during the fiscal year ending 2002.

- G - Earnings from continuing operations per common share:

Basic earnings per share (EPS) is computed by dividing the earnings measure by the weighted average number of shares of common stock outstanding. Diluted EPS is computed assuming the exercise of stock options, conversion of preferred stock and the issuance of stock as incentive compensation to certain employees. Also in the diluted computations, earnings from continuing operations and net earnings are reduced by an incremental contribution to the Employee Stock Ownership Plan (ESOP). This contribution is the after-tax difference between the income the ESOP would have received in preferred stock dividends and the dividend on the common shares assumed to have been outstanding. The assumed conversion of stock options having an exercise price higher than the weighted average market price of the underlying share is not taken into account in the diluted EPS computation as the effect would be antidilutive. The following table reconciles the numerators and denominators of the basic and diluted earnings per share computations.

| (Share amounts in millions)                 | 2001 Basic |           | 2001 D  |
|---|------------|-----------|---------|
|   | Actual     | Pro forma | Actual  |
| EPS numerator:                              |            |           |         |
| Earnings from continuing operations         | \$1,291    | \$1,022   | \$1,291 |
| Less: Preferred stock dividends, net of tax | (13)       | (13)      | --      |
| Less: ESOP contribution, net of tax         | --         | --        | (8)     |
| Earnings from continuing operations         |            |           |         |

Edgar Filing: PHARMACIA CORP /DE/ - Form 8-K

|  |         |         |         |
|--|---------|---------|---------|
| available to common shareholders                   | \$1,278 | \$1,009 | \$1,283 |
| -----  |         |         |         |
| EPS denominator:                                   |         |         |         |
| Average common shares outstanding                  | 1,298   | 1,298   | 1,298   |
| Effect of dilutive securities:                     |         |         |         |
| Stock options and stock warrants                   | --      | --      | 12      |
| Convertible instruments and incentive compensation | --      | --      | 12      |
| -----  |         |         |         |
| Total shares                                       | 1,298   | 1,298   | 1,322   |
| -----  |         |         |         |
| Earnings from continuing operations per share      | \$ 0.98 | \$ 0.78 | \$ 0.97 |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PHARMACIA CORPORATION  
(Registrant)

Date: April 30, 2002

/s/ R.G. THOMPSON

-----  
R.G. Thompson  
Senior Vice President  
and Corporate Controller